Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study.

Date publication

octobre 2021

Journal

Clinical colorectal cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie , Pr BORG Christophe , Pr BOUCHE Olivier , Pr CONROY Thierry , Pr GHIRINGHELLI François , Dr GOBBO Jessica

Tous les auteurs :
Bertaut A, Touchefeu Y, Blanc J, Bouché O, François E, Conroy T, Artru P, Adenis A, Gobbo J, Borg C, Ghiringhelli F, Bennouna J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34838460

Résumé

We have previously showed that for patients with wild-type RAS metastatic colorectal cancer (mCRC) progressing after bevacizumab plus chemotherapy, bevacizumab continuation plus a switch of chemotherapy is the most appropriate option (PRODIGE 18 phase II study). Here we aimed to determine treatment impact in patient's Health-Related Quality Of Life (HRQoL) in PRODIGE18 study.

Mots clés

Bevacizumab, Cetuximab, Health-related quality of life, Metastatic colorectal cancer, PRODIGE18, Second line treatment, Treatment selection

Référence

Clin Colorectal Cancer. 2021 Oct 3;: